“…In this context, several efforts have been already devoted to discovering new signal reporters to increase ELISA sensitivity [3] and to pinpoint capturing agents, i.e., mimetics [8], able to flank and/or supplant antibodies that generally are expensive and sensitive to environmental conditions. Looking at mimetic capturing agents, the literature has highlighted aptamers and molecularly imprinted polymers (MIPs) as the most promising ones to develop diagnostic "antibody-free" ELISA-like format assays, i.e., enzymelinked oligonucleotide assay (ELONA) [6,9], biomimetic enzyme-linked immunoassay (BELISA) [10][11][12][13][14][15][16][17][18][19], pseudo-ELISA [7,[20][21][22][23], or nanoparticle-based assay (MINA) [1,15,[24][25][26][27][28][29]. At present, a positive imbalance of the literature is in favor of aptamers, with only a few reports about MIPs starting from 2014.…”